Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.25 CAD 0.45% Market Closed
Market Cap: 132.7m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Intrinsic Value

The intrinsic value of one RX stock under the Base Case scenario is 9.51 CAD. Compared to the current market price of 11.25 CAD, Biosyent Inc is Overvalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RX Intrinsic Value
9.51 CAD
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Biosyent Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Biosyent Inc

Provide an overview of the primary business activities
of Biosyent Inc.

What unique competitive advantages
does Biosyent Inc hold over its rivals?

What risks and challenges
does Biosyent Inc face in the near future?

Summarize the latest earnings call
of Biosyent Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biosyent Inc.

Provide P/S
for Biosyent Inc.

Provide P/E
for Biosyent Inc.

Provide P/OCF
for Biosyent Inc.

Provide P/FCFE
for Biosyent Inc.

Provide P/B
for Biosyent Inc.

Provide EV/S
for Biosyent Inc.

Provide EV/GP
for Biosyent Inc.

Provide EV/EBITDA
for Biosyent Inc.

Provide EV/EBIT
for Biosyent Inc.

Provide EV/OCF
for Biosyent Inc.

Provide EV/FCFF
for Biosyent Inc.

Provide EV/IC
for Biosyent Inc.

Show me price targets
for Biosyent Inc made by professional analysts.

What are the Revenue projections
for Biosyent Inc?

How accurate were the past Revenue estimates
for Biosyent Inc?

What are the Net Income projections
for Biosyent Inc?

How accurate were the past Net Income estimates
for Biosyent Inc?

What are the EPS projections
for Biosyent Inc?

How accurate were the past EPS estimates
for Biosyent Inc?

What are the EBIT projections
for Biosyent Inc?

How accurate were the past EBIT estimates
for Biosyent Inc?

Compare the revenue forecasts
for Biosyent Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biosyent Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biosyent Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biosyent Inc compared to its peers.

Compare the P/E ratios
of Biosyent Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Biosyent Inc with its peers.

Analyze the financial leverage
of Biosyent Inc compared to its main competitors.

Show all profitability ratios
for Biosyent Inc.

Provide ROE
for Biosyent Inc.

Provide ROA
for Biosyent Inc.

Provide ROIC
for Biosyent Inc.

Provide ROCE
for Biosyent Inc.

Provide Gross Margin
for Biosyent Inc.

Provide Operating Margin
for Biosyent Inc.

Provide Net Margin
for Biosyent Inc.

Provide FCF Margin
for Biosyent Inc.

Show all solvency ratios
for Biosyent Inc.

Provide D/E Ratio
for Biosyent Inc.

Provide D/A Ratio
for Biosyent Inc.

Provide Interest Coverage Ratio
for Biosyent Inc.

Provide Altman Z-Score Ratio
for Biosyent Inc.

Provide Quick Ratio
for Biosyent Inc.

Provide Current Ratio
for Biosyent Inc.

Provide Cash Ratio
for Biosyent Inc.

What is the historical Revenue growth
over the last 5 years for Biosyent Inc?

What is the historical Net Income growth
over the last 5 years for Biosyent Inc?

What is the current Free Cash Flow
of Biosyent Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biosyent Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biosyent Inc

Current Assets 30.1m
Cash & Short-Term Investments 17.4m
Receivables 5.8m
Other Current Assets 6.9m
Non-Current Assets 11.4m
Long-Term Investments 8.4m
PP&E 1.3m
Intangibles 1.2m
Other Non-Current Assets 495.5k
Current Liabilities 4.9m
Accounts Payable 4.5m
Other Current Liabilities 435.9k
Non-Current Liabilities 1.2m
Long-Term Debt 942.2k
Other Non-Current Liabilities 210k
Efficiency

Earnings Waterfall
Biosyent Inc

Revenue
33.8m CAD
Cost of Revenue
-6.8m CAD
Gross Profit
27m CAD
Operating Expenses
-18.7m CAD
Operating Income
8.3m CAD
Other Expenses
-1.2m CAD
Net Income
7.2m CAD

Free Cash Flow Analysis
Biosyent Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 2024, BioSyent reported record revenues of just under $9 million, up 12% year-over-year, driven by strong performances across its Canadian pharmaceutical brands. EBITDA for the quarter exceeded $2 million, with net income just under $1.6 million. The company has achieved its 56th consecutive profitable quarter, aided by innovative product launches and strategic investments. BioSyent’s EBITDA and net income margins grew to 25% and 20%, respectively. The company expects continued revenue and profit growth, with new products and strategic acquisitions on the horizon, including a promising endocrinology product slated for a 2026 launch.

What is Earnings Call?
Fundamental Scores

RX Profitability Score
Profitability Due Diligence

Biosyent Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Positive Free Cash Flow
Exceptional ROIC
71/100
Profitability
Score

Biosyent Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

RX Solvency Score
Solvency Due Diligence

Biosyent Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Biosyent Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RX Price Targets Summary
Biosyent Inc

Wall Street analysts forecast RX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RX is 11.22 CAD with a low forecast of 11.11 CAD and a high forecast of 11.55 CAD.

Lowest
Price Target
11.11 CAD
1% Downside
Average
Price Target
11.22 CAD
0% Downside
Highest
Price Target
11.55 CAD
3% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RX?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for RX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Biosyent Inc Logo
Biosyent Inc

Country

Canada

Industry

Pharmaceuticals

Market Cap

130.3m CAD

Dividend Yield

1.56%

Description

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

Contact

ONTARIO
Mississauga
2476 Argentia Road, Suite 402
+19052060013.0
www.biosyent.com

IPO

1981-05-22

Employees

-

Officers

Chairman, CEO & President
Mr. René C. Goehrum
VP of Finance & CFO
Mr. Robert J. March
Vice President of Corporate Development
Mr. Joost van der Mark
Director of Human Resources
Ms. Neelu Atwal

See Also

Discover More
What is the Intrinsic Value of one RX stock?

The intrinsic value of one RX stock under the Base Case scenario is 9.51 CAD.

Is RX stock undervalued or overvalued?

Compared to the current market price of 11.25 CAD, Biosyent Inc is Overvalued by 15%.

Back to Top